Stephens Scott P, Decoons Ryan M, Szerlip Benjamin W, Goubeaux Craig A, Schuette Hayden B, Glazier Matthew T, Braden Abigail M, Hendrickson Luke A, Comisar Bruce R
OrthoNeuro Shoulder Division, Columbus, OH, USA.
Medical College of Georgia Department of Surgery, Augusta, GA, USA.
JSES Int. 2023 Jan 5;7(2):270-276. doi: 10.1016/j.jseint.2022.12.015. eCollection 2023 Mar.
The purpose of this study is to compare the 90-day complications and readmission rates between patients undergoing total shoulder arthroplasty (TSA) in an ambulatory surgery center (ASC) with glenoid bone loss requiring an augmented glenoid component compared to patients without bone loss.
This is a retrospective cohort study of patients undergoing outpatient TSA at an ASC (2018-2021). Readmission, direct transfer, and complications were recorded. Major and minor complications were compared. Secondary outcomes included operative time, estimated blood loss, range of motion, and patient-reported outcome measures.
There were 44 patients (45 shoulders) included in the study, 20 with augmented implants for glenoid bone loss and 25 nonaugmented with a concentric glenoid. There were no statistical differences in demographics. Two complications were seen in both the augmented and nonaugmented groups (10% vs. 8%). There were no readmissions or direct transfers. The augmented group had significantly increased preoperative glenoid retroversion (23° vs. 9°, < .05), posterior humeral head subluxation (78% vs. 61%., < .05), and longer operative time (124.4 min vs. 112.3 min., < .05). Patient-specific instrumentation was used in 60% of augmented cases and 29% of nonaugmented cases.
There was no significant difference in complications, direct transfers, or readmissions between patients with and without glenoid bone loss being treated in an outpatient ASC. The augmented group had significantly worse preoperative deformities, longer operative times, and increased utilization of patient-specific instrumentation. Outpatient TSA in the setting of glenoid bone loss requiring augmentation was found to be safe and effective at a stand-alone ASC.
本研究的目的是比较在门诊手术中心(ASC)接受全肩关节置换术(TSA)且盂骨丢失需要增加盂部件的患者与无骨丢失患者之间的90天并发症和再入院率。
这是一项对在ASC接受门诊TSA的患者(2018 - 2021年)进行的回顾性队列研究。记录再入院、直接转院和并发症情况。比较主要和次要并发症。次要结局包括手术时间、估计失血量、活动范围和患者报告的结局指标。
本研究纳入44例患者(45个肩关节),20例使用增加植入物治疗盂骨丢失,25例未增加植入物,使用同心盂。人口统计学方面无统计学差异。增加植入物组和未增加植入物组均出现2例并发症(10%对8%)。无再入院或直接转院情况。增加植入物组术前盂后倾显著增加(23°对9°,P <.05),肱骨头后脱位发生率更高(78%对61%,P <.05),手术时间更长(124.4分钟对112.3分钟,P <.05)。60%的增加植入物病例和29%的未增加植入物病例使用了定制器械。
在门诊ASC治疗的有和没有盂骨丢失的患者之间,并发症、直接转院或再入院方面无显著差异。增加植入物组术前畸形更严重,手术时间更长,定制器械的使用增加。发现在独立的ASC中,对于需要增加植入物的盂骨丢失情况,门诊TSA是安全有效的。